QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.067884v1 310/3/905    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rinaldi-Carmona, M. Articles by Le Fur, G. Search for Related Content PubMed PubMed Citation Articles by Rinaldi-Carmona, M. Articles by Le Fur, G.

NEUROPHARMACOLOGY

SR147778 [5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a New Potent and Selective Antagonist of the CB1 Cannabinoid Receptor: Biochemical and Pharmacological Characterization

Sanofi-Synthelabo Recherche, Montpellier, France

Based on binding, functional, and pharmacological data, this study introduces SR147778 [5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide] as a highly potent, selective, and orally active antagonist for the CB1 receptor. This compound displays nanomolar affinity (K_i = 0.56 and 3.5 nM) for both the rat brain and human CB1 recombinant receptors, respectively. It has low affinity (K_i = 400 nM) for both the rat spleen and human CB2 receptors. Furthermore, it shows no affinity for any of the over 100 targets investigated (IC₅₀ > 1 µM). In vitro, SR147778 antagonizes the inhibitory effects of CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol] on both the mouse vas deferens contractions (pA₂ value = 8.1) and on forskolin-stimulated adenylyl cyclase activity in the U373 MG cell lines (pA₂ value = 8.2) but not in Chinese hamster ovary (CHO) cells permanently expressing the human peripheral cannabinoid receptor (hCB2). SR147778 is able to block the mitogen-activated protein kinase activity induced by CP 55,940 in the CHO cell line expressing human brain cannabinoid receptor (IC₅₀ = 9.6 nM) but was inactive in cells expressing hCB2. After oral administration, SR147778 displaced the ex vivo [³H]-CP 55,940 binding to mouse brain membranes (ED₅₀ = 3.8 mg/kg) with a long duration of action, whereas it did not interact with the CB2 receptor expressed in the mouse spleen. Using different routes of administration, SR147778 (0.3–3 mg/kg) is shown to antagonize pharmacological effects (hypothermia, analgesia, and gastrointestinal transit) induced by R-(+)-(2,3-dihydro-5-methyl-3-[{4-morpholinyl}methyl] pyrol [1,2,3-de]-1,4-benzoxazin-6-yl)(1-naphthalenyl) methanone in mice. Finally, per se, SR147778 (0.3–10 mg/kg) is able to reduce ethanol or sucrose consumption in mice and rats and food intake in fasted and nondeprived rats.

Address correspondence to: Murielle Rinaldi-Carmona, Sanofi-Synthelabo Recherche, 371 Rue du Professeur J Blayac, 34184 Montpellier cedex, France. E-mail: murielle.rinaldi-carmona{at}sanofi-synthelabo.com

This article has been cited by other articles:

				C. S. Elangbam REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns Vet. Pathol., January 1, 2009; 46(1): 10 - 24. [Abstract] [Full Text] [PDF]

				F. Montecucco, F. Burger, F. Mach, and S. Steffens CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1145 - H1155. [Abstract] [Full Text] [PDF]

				U. Pagotto, G. Marsicano, D. Cota, B. Lutz, and R. Pasquali The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance Endocr. Rev., February 1, 2006; 27(1): 73 - 100. [Abstract] [Full Text] [PDF]

				B. Le Foll and S. R. Goldberg Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 875 - 883. [Abstract] [Full Text] [PDF]

				F. RODRIGUEZ de FONSECA, I. DEL ARCO, F. J. BERMUDEZ-SILVA, A. BILBAO, A. CIPPITELLI, and M. NAVARRO THE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY Alcohol Alcohol., January 1, 2005; 40(1): 2 - 14. [Abstract] [Full Text] [PDF]

				J. MANZANARES, S. ORTIZ, J. M. OLIVA, S. PEREZ-RIAL, and T. PALOMO INTERACTIONS BETWEEN CANNABINOID AND OPIOID RECEPTOR SYSTEMS IN THE MEDIATION OF ETHANOL EFFECTS Alcohol Alcohol., January 1, 2005; 40(1): 25 - 34. [Abstract] [Full Text] [PDF]

				G. L. GESSA, S. SERRA, G. VACCA, M. A. M. CARAI, and G. COLOMBO SUPPRESSING EFFECT OF THE CANNABINOID CB1 RECEPTOR ANTAGONIST, SR147778, ON ALCOHOL INTAKE AND MOTIVATIONAL PROPERTIES OF ALCOHOL IN ALCOHOL-PREFERRING sP RATS Alcohol Alcohol., January 1, 2005; 40(1): 46 - 53. [Abstract] [Full Text] [PDF]